Cellipont Bioservices announced the completion of its ballroom-style cleanroom, featuring a state-of-the-art 50-liter single-use bioreactor. This facility expansion marks a major milestone in Cellipont's continued investment to meet the growing demand for advanced manufacturing of exosome, induced pluripotent stem cell (iPSC), and mesenchymal stem cell (MSC) therapies.
The addition of the 50-liter single-use bioreactor significantly expands Cellipont's cGMP-compliant capacity, enabling clients to seamlessly transition from early development to large-scale, commercial manufacturing. This system enhances batch consistency, process scalability, and production efficiency, accelerating the path from clinical development to commercialization for allogeneic therapies.
Key Benefits for Cell Therapy Innovators
- True Scalability: Seamlessly scale processes from pilot to commercial volumes
- Batch Consistency: Advanced bioprocessing ensures reliable, donor-derived product quality
- Accelerated Timelines: Streamlined scale-up reduces complexity and speeds market entry
"Our newest cleanroom and 50-liter single-use bioreactor represent a significant milestone in our commitment to supporting the next generation of cell therapies," said Darren Head, CEO of Cellipont. "We're excited to help our clients achieve the consistency, throughput, and regulatory compliance needed for clinical and commercial success." He added, "By investing in advanced manufacturing capabilities, we are empowering innovators to bring transformative therapies to patients faster and more reliably than ever before."